Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It?

Published:November 06, 2022DOI:
      A recent study published in the Journal of the American Medical Association, “Effect of Aspirin versus Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial,” has again raised controversy concerning the optimal modality for venous thromboembolism (VTE) prophylaxis [
      • Sidhu V.S.
      • Kelly T.L.
      • Pratt N.
      • Graves S.E.
      • Buchbinder R.
      • Adie S.
      • et al.
      CRISTAL Study Group
      Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial.
      ]. The authors should be congratulated on completing this prospective, randomized, crossover, and registry-nested trial. This massive undertaking involved enrolling a large number of patients from 31 centers in Australia. The authors of the study reported that the incidence of symptomatic VTE was significantly higher in patients receiving aspirin (3.45%) compared with enoxaparin (1.82%).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Arthroplasty
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sidhu V.S.
        • Kelly T.L.
        • Pratt N.
        • Graves S.E.
        • Buchbinder R.
        • Adie S.
        • et al.
        • CRISTAL Study Group
        Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial.
        JAMA. 2022; 328: 719-727
        • Abdel M.P.
        • Meneghini R.M.
        • Berry D.J.
        Current practice trends in primary hip and knee arthroplasties among members of the American association of hip and knee surgeons: an update during the COVID-19 pandemic.
        J Arthroplasty. 2021; 36: S40-S44
        • The ICM-VTE Hip & Knee Delegates
        Recommendations from the ICM-VTE: hip & knee.
        J Bone Joint Surg Am. 2022; 104: 180-231
        • Huang R.C.
        • Parvizi J.
        • Hozack W.J.
        • Chen A.F.
        • Austin M.S.
        Aspirin is as effective as and safer than warfarin for patients at higher risk of venous thromboembolism undergoing total joint arthroplasty.
        J Arthroplasty. 2016; 31: 83-86
        • Bayley E.
        • Brown S.
        • Bhamber N.S.
        • Howard P.W.
        Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study.
        Bone Joint J. 2016; 98-B: 585-588
        • Rondon A.J.
        • Shohat N.
        • Tan T.L.
        • Goswami K.
        • Huang R.C.
        • Parvizi J.
        The use of aspirin for prophylaxis Against venous thromboembolism decreases mortality following primary total joint arthroplasty.
        J Bone Joint Surg Am. 2019; 101: 504-513
        • Huang R.
        • Buckley P.S.
        • Scott B.
        • Parvizi J.
        • Purtill J.J.
        Administration of aspirin as a prophylaxis Agent against venous thromboembolism results in lower incidence of periprosthetic joint infection.
        J Arthroplasty. 2015 Sep; 30: 39-41
        • Kahlenberg C.A.
        • Richardson S.S.
        • Schairer W.W.
        • Sculco P.K.
        Type of anticoagulant used after total knee arthroplasty affects the rate of knee manipulation for postoperative stiffness.
        J Bone Joint Surg Am. 2018; 100: 1366-1372
        • Shohat N.
        • Ludwick L.
        • Sutton R.
        • Chisari E.
        • Parvizi J.
        Aspirin administered for venous thromboembolism prophylaxis may protect against stiffness following total knee arthroplasty.
        J Arthroplasty. 2022; 37: 953-957
        • Li W.T.
        • Klement M.R.
        • Foltz C.
        • Sinensky A.
        • Yazdi H.
        • Parvizi J.
        Highlighting the roles of anemia and aspirin in predicting ninety-day readmission following aseptic revision total joint arthroplasty.
        J Arthroplasty. 2020; 35: 490-494
        • Goswami K.
        • Tan T.L.
        • Rondon A.J.
        • Shohat N.
        • Yayac M.
        • Schlitt P.K.
        • et al.
        Aspirin thromboprophylaxis confers No increased risk for aseptic loosening following cementless primary hip arthroplasty.
        J Arthroplasty. 2019; 34: 2978-2982
        • Singh V.
        • Shahi A.
        • Saleh U.
        • Tarabichi S.
        • Oliashirazi A.
        Persistent wound drainage among total joint arthroplasty patients receiving aspirin vs coumadin.
        J Arthroplasty. 2020; 35: 3743-3746
        • Patel V.P.
        • Walsh M.
        • Sehgal B.
        • Preston C.
        • DeWal H.
        • Di Cesare P.E.
        Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty.
        J Bone Joint Surg Am. 2007; 89: 33-38
        • Raphael I.J.
        • Tischler E.H.
        • Huang R.
        • Rothman R.H.
        • Hozack W.J.
        • Parvizi J.
        Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?.
        Clin Orthop Relat Res. 2014; 472: 482-488
        • Anderson D.R.
        • Dunbar M.
        • Murnaghan J.
        • Kahn S.R.
        • Gross P.
        • Forsythe M.
        • et al.
        Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty.
        N Engl J Med. 2018; 378: 699-707
        • Matharu G.S.
        • Kunutsor S.K.
        • Judge A.
        • Blom A.W.
        • Whitehouse M.R.
        Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials.
        JAMA Intern Med. 2020; 180: 376-384
        • Pulmonary Embolism Prevention (PEP) trial Collaborative Group
        Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary Embolism Prevention (PEP) trial.
        Lancet. 2000; 355: 1295-1302
        • Ren Y.
        • Cao S.L.
        • Li Z.
        • Luo T.
        • Feng B.
        • Weng X.S.
        Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial.
        Chin Med J (Engl). 2021; 134: 164-172
        • Anderson D.R.
        • Dunbar M.J.
        • Bohm E.R.
        • Belzile E.
        • Kahn S.R.
        • Zukor D.
        • et al.
        Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
        Ann Intern Med. 2013; 158: 800-806
        • Westrich G.H.
        • Bottner F.
        • Windsor R.E.
        • Laskin R.S.
        • Haas S.B.
        • Sculco T.P.
        VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
        J Arthroplasty. 2006; 21: 139-143
        • Cook A.J.
        • Delong E.
        • Murray D.M.
        • Vollmer W.M.
        • Heagerty P.J.
        Statistical lessons learned for designing cluster randomized pragmatic clinical trials from the NIH Health Care Systems Collaboratory Biostatistics and Design Core.
        Clin Trials. 2016; 13: 504-512